Roche's Ocrevus (ocrelizumab) is better at controlling disease activity in relapsing multiple sclerosis than German Merck's Rebif (interferon beta-1a), according to ...

Avonex® IFN-β-1a im. weekly RRMS and 'early therapy' in patients with an initial demyelinating event and high risk of occurrence of clinically definite MS Rebif® IFN-β-1a sc. three times a ...

The primary growth driver for the Rebif market is the increasing prevalence of multiple sclerosis (MS), a chronic autoimmune disease impacting the central nervous system. .Several factors ...

Accelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in healthcare sales in the third quarter, and a rise in its full-year ...

In the phase 2 trials, 20% of Campath-treated patients developed thyroid disorders compared to 3% on Rebif. Krupp notes, however, that thyroid trouble seems to occur with MS anyway, for reasons ...

Mountz went to a local hospital and was diagnosed with multiple sclerosis. The doctors immediately administered steroids and, a few months later, put him on a regimen of Rebif, a recombinant form ...